Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

To join this study, you need to be at least 18 years old and have been diagnosed with stomach, gastro-oesophageal junction, oesophageal, or pancreatic cancer. Your cancer must have spread or be advanced, and you should have already tried at least one other treatment for it that didn't work as well as hoped. Doctors will also check that your cancer cells have a specific marker called CLDN18.2, as the study medicine targets this.

For your safety, there are some reasons why you might not be able to join. For example, if you have certain heart problems, active infections like HIV or hepatitis, or certain autoimmune conditions. You also shouldn't have had specific severe side effects from similar types of treatment in the past.

Doctors will also need to make sure your general health is good enough to take part, checking things like your blood tests and how well your organs are working. They will also need to see that your cancer can be measured accurately to see if the treatment is working.

If you decide to take part, you'll receive the study medicine, AZD5863. This will either be given into a vein (like a drip) or as an injection under your skin. The study will involve regular visits to the hospital for the medicine, blood tests, and scans to check on your health and whether the medicine is affecting your cancer. The study is divided into two parts: first, a small group will help doctors find the best dose (this might involve a shorter or longer stay in the hospital depending on how you react), and then more people will receive that dose. You would continue treatment as long as it's helping you and you're not experiencing severe side effects. The total duration of your participation will depend on how you respond to the treatment.